professor of cancer epidemialogy at Cambridge University, cast doubt on
the WCRF’s findings. “I do not think that the published data are
sufficiently robust to conclude that three drinks a day specifically is
associated with an increased risk of primary liver cancer,” he said.
strongly defends the IARC process and insists that there is a set of
clear rules that lays out which studies can be considered by the experts
convened by the IARC. These are broadly limited to peer-reviewed
publications and government reports, leading to the rejection of a
number of industry-submitted studies.
States and other international regulatory bodies have backed the safety
of glyphosate when used as directed, but the IARC report cited studies
that raised concerns about glyphosate and impacts on health. Monsanto
says such studies are invalid. But critics say they merit attention.
remains to be determined exactly how these uncommon genetic variants
and/or nearby sections of DNA offset the properties of aspirin that
guard against colorectal cancer in most people. But researchers
speculate that it may have something to do with an increased tendency
towards inflammation that is for some reason resistant to aspirin’s
encourages clinical trial investigators to review data from their
completed clinical trials and treating oncologists to look back in their
patient records to identify potential cases of exceptional responses
and submit them for consideration. Clinicians who submit cases also will
become part of the analysis team for that case.
cancer nod put Bristol-Myers ahead in that field, at least in squamous
non-small cell lung cancer (NSCLC) patients. Keytruda is eying an NSCLC
indication as well, and given the data at hand, the Merck med may get an
FDA approval covering a broader range of patients.
the first anti-PD-1 therapy to demonstrate a survival advantage compared
to the standard of care for the first-line treatment of advanced
melanoma. These data will be presented in the opening plenary session at
the American Association of Cancer Research (AACR) Annual Meeting in
Philadelphia, April 18-22.
France-based company now plans to offer 4.75 million shares. At its
Monday trading price on the Euronext Paris of $41.41, Cellectis would
raise $197 million, or 53% more than previously anticipated
Pitt’s decision not to remove her uterus was consistent with what
experts recommended. “There is no research showing that having a BRCA
mutation puts women at risk for uterine cancer,” said Dr. Jamie
Bakkum-Gamez, a gynecologic oncologist at the Mayo Clinic.
Dr Karen Liu,
chair of gynecologic oncology at University of Texas’s MD Anderson
Cancer Center, said that Jolie’s piece was also important because it
illustrated the “emotional rollercoaster” women faced when considering
having the procedure.
“What we can
see here is that better cancer survival rates are not unachievable. If
countries like Sweden, France, Finland and Austria can achieve these
rates, then the UK can and should, bridge the gap."